APA (7th ed.) Citation

Sumantra Sarkar, Chandrakant Bokade, Kapil Garg, Ravi Kumar, Jayesh Sanmukhani, & Ravindra Mittal. (2021). Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy children (6 months to 17 years of age): A randomized, multicenter, phase III clinical trial. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Sumantra Sarkar, Chandrakant Bokade, Kapil Garg, Ravi Kumar, Jayesh Sanmukhani, and Ravindra Mittal. Immunogenicity and Safety of the First Indigenously Developed Indian Tetravalent Influenza Vaccine (split Virion) in Healthy Children (6 Months to 17 Years of Age): A Randomized, Multicenter, Phase III Clinical Trial. Taylor & Francis Group, 2021.

MLA (9th ed.) Citation

Sumantra Sarkar, et al. Immunogenicity and Safety of the First Indigenously Developed Indian Tetravalent Influenza Vaccine (split Virion) in Healthy Children (6 Months to 17 Years of Age): A Randomized, Multicenter, Phase III Clinical Trial. Taylor & Francis Group, 2021.